For most of human history, brain fog has been priced into the human condition, a steady tax on memory that compounds quietly after fifty. Scientists call the underlying process "neuroinflammaging" (a slow burn of inflammation deep in the brain's memory regions), and have long considered it a one-way street.
Researchers at Texas A&M led by Dr. Ashok Shetty have now shown that the street runs both ways. In a study published in the Journal of Extracellular Vesicles, just two doses of a nasal spray dramatically reduced brain inflammation, restored neurons' cellular power plants, and significantly improved memory, with effects holding for months. The spray contains microscopic biological packages (extracellular vesicles, harvested from human neural stem cells) carrying microRNA cargo. Delivered through the nose, they slip past the blood-brain barrier and switch off two of the main inflammation pathways linked to cognitive decline. A US patent has been filed.
🧐 What's in it for me? It's a mouse study, so calibrate expectations accordingly. But the underlying lever (switching off inflammation pathways in aged brains) is one of the most plausible in longevity science, and intranasal delivery is one of the few routes that can get large molecules into the brain without having to get the drill out. If any of this translates, dementia prevention starts looking less like an aspiration and more like a logistics problem.
💵 Out of the Lab: Brain aging is the single largest unsolved problem in medicine by total addressable market. US dementia cases are projected to roughly double by 2060, and a small group of researcher-founded companies are pushing the underlying biology toward the clinic.
Aruna Bio, a University of Georgia spinout founded by stem cell researcher Steven Stice, holds an FDA-cleared IND for AB126, an unmodified neural-derived extracellular vesicle therapy. It is the closest direct commercial analogue to the Texas A&M work.
BioAge Labs (NASDAQ: BIOA), founded by aging biologist Kristen Fortney, is running Phase 2 trials of BGE-102, a brain-penetrant inhibitor of the NLRP3 inflammasome, one of the same inflammation pathways the nasal spray targets.
Cognito Therapeutics, spun out of MIT by neuroscientists Li-Huei Tsai and Ed Boyden, holds FDA Breakthrough Device Designation for its gamma-stimulation Alzheimer's device, currently in pivotal trials.
Until next time.
Like what you're reading? Share toast with a friend.